Pharmaceutical

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the full year and fourth quarter ended December 31, 2017. As quoted in the press release: “2017 was a defining year for Strongbridge, marked by rapid transformation and …

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the full year and fourth quarter ended December 31, 2017.

As quoted in the press release:

“2017 was a defining year for Strongbridge, marked by rapid transformation and growth as we became a revenue-generating rare disease company. As a result of the early launch uptake of KEVEYIS, the first and only FDA-approved treatment for Primary Periodic Paralysis (PPP), we made the decision to more than double our field-based team in the fourth quarter to meet growing market demand and position us for success in 2018 and beyond. This expanded investment reflects the significant opportunity in the market, the need to raise awareness of this ultra-rare disease and our commitment to patient communities, such as PPP, that may otherwise go ignored,” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma.

Click here to read the full press release.

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1821.29+2.72
Silver20.87+0.05
Copper3.79+0.01
Palladium1942.50+73.50
Platinum929.49+19.49
Oil112.40+0.64
Heating Oil4.05-0.06
Natural Gas6.75+0.18

DOWNLOAD FREE REPORTS

×